Company Hangzhou Tigermed Consulting Co., Ltd
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.53 CNY | -1.46% |
|
-5.21% | -0.30% |
Business description: Hangzhou Tigermed Consulting Co., Ltd
- provision of clinical trial services and related technological services (51.8%);
- provision of clinical research consulting services (48.2%).
China accounts for 46% of sales.
Number of employees: 10,185
Sales by Activity: Hangzhou Tigermed Consulting Co., Ltd
| Fiscal Period: December | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) |
|---|---|---|---|---|---|
Clinical-Related and Laboratory Services | - | - | 2.88B | 3.12B | 3.3B |
Clinical Trial Solutions | - | - | 4.13B | 4.17B | 3.18B |
Service Industry | 3.19B | 5.21B | - | - | - |
Unallocated Other | - | - | 83.93M | 94.93M | 129M |
Geographical breakdown of sales: Hangzhou Tigermed Consulting Co., Ltd
| Fiscal Period: December | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) |
|---|---|---|---|---|---|
China | 1.91B | 2.76B | 3.6B | 4.23B | 3.55B |
Overseas | 1.29B | 2.46B | 3.48B | 3.15B | 3.06B |
Executive Committee: Hangzhou Tigermed Consulting Co., Ltd
| Manager | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 57 | - |
Hao Wu
PSD | President | 59 | 2019-12-31 |
Cheng Cheng Yang
DFI | Director of Finance/CFO | 52 | 2022-10-20 |
Zeng Yu Wen
COO | Chief Operating Officer | 45 | - |
Xiaori Li
SEC | Corporate Secretary | 43 | 2021-09-16 |
Composition of the Board of Directors: Hangzhou Tigermed Consulting Co., Ltd
| Director | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
BRD | Director/Board Member | 57 | 2004-12-31 |
Bing Hui Zhang
CHM | Chairman | 63 | 2020-04-27 |
Xiao Ping Ye
CHM | Chairman | 63 | - |
Yu Wen Liu
BRD | Director/Board Member | 53 | 2024-03-20 |
Zhi Min Chen
BRD | Director/Board Member | 66 | - |
Hua Gang Yuan
BRD | Director/Board Member | 53 | 2023-04-24 |
Kai Yu Liu
BRD | Director/Board Member | 56 | 2020-03-31 |
Hao Wu
BRD | Director/Board Member | 59 | 2019-12-31 |
Zeng Yu Wen
BRD | Director/Board Member | 45 | 2023-05-22 |
Holdings: Hangzhou Tigermed Consulting Co., Ltd
| Name | Equities | % | Valuation |
|---|---|---|---|
| 1,314,504,090 | 64.57% | 178 M $ | |
DREAMCIS, INC. 59.34% | 14,123,680 | 59.34% | 59 M $ |
Company details: Hangzhou Tigermed Consulting Co., Ltd
Hangzhou Tigermed Consulting Co., Ltd.
20/F Block 8, Room 2001-2010
310051, Hangzhou
+86 571 2888 7227
http://www.tigermed.net
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.46% | -5.21% | -0.42% | -48.95% | 6.78B | |
| -1.64% | -6.54% | -8.95% | -8.31% | 45.49B | |
| -0.16% | -4.42% | +23.83% | +37.84% | 33.41B | |
| -4.00% | -14.47% | +15.30% | +44.37% | 31.32B | |
| +1.85% | +1.88% | -5.95% | -12.51% | 29.29B | |
| +0.47% | -2.96% | +167.82% | +354.42% | 19.5B | |
| -0.71% | -1.12% | +73.24% | +120.04% | 14.77B | |
| +1.54% | +4.24% | +41.34% | +153.67% | 13.36B | |
| -1.95% | -6.65% | +21.36% | +2.76% | 13.21B | |
| +1.66% | -7.96% | +134.14% | +117.03% | 12.23B | |
| Average | -0.44% | -3.37% | +46.17% | +76.04% | 21.94B | |
| Weighted average by Cap. | -0.69% | -4.34% | +34.28% | +62.83% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300347 Stock
- Company Hangzhou Tigermed Consulting Co., Ltd
Select your edition
All financial news and data tailored to specific country editions
